http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011121300-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B64D39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D271-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D271-113 |
| filingDate | 2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011121300-A |
| titleOfInvention | 1,3,4-OXADADIAZOLE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF DIABETES |
| abstract | 1. The compound of formula (I) or a pharmaceutically acceptable salt of n is 0, 1, 2 or 3, R is independently selected from fluoro, chloro, bromo, trifluoromethyl, methoxy, difluoromethoxy and trifluoromethoxy, and Z is a carboxy group or a mimetic thereof, or bioisostere, hydroxyl, hydroxymethyl or —CONRbRc, where Rb and Rc are independently selected from hydrogen and a (C1-4) alkyl group, which may be optionally substituted with a carboxy group or its mimetic or bioisostere. 2. The compound of formula (IA) according to claim 1, or a pharmaceutically acceptable salt of n and R thereof, are as defined in claim 1.3. The compound of formula (IB) according to claim 1, or a pharmaceutically acceptable salt of n and R thereof, are as defined in 1.4. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein n is 2 or 3, and R is fluoro. The compound according to claim 1, selected from (1r, 4r) -4- (3-fluoro-4- (5- (4- (trifluoromethyl) phenylamino) -1,3,4-oxadiazole-2-carboxamido) phenyl) cyclohexanecarboxylic acids; (1r, 4r) -4- (4- (5- (4- (difluoromethoxy) phenylamino) -1,3,4-oxadiazole-2-carboxamido) -3-fluorophenyl) cyclohexanecarboxylic acid; (1r, 4r) -4- (3-fluoro-4- (5- (4- (trifluoromethoxy) phenylamino) -1,3,4-oxadiazole-2-carboxamido) phenyl) cyclohexanecarboxylic acid; (1r, 4r) -4- (4- (5- (3-chlorophenylamino) -1,3,4-oxadiazole-2-carboxamido) -3-fluorophenyl) cyclohexanecarboxylic acid; (1r, 4r) -4- (4- (5- (3,4-difluorophenylamino) -1,3,4-oxadiazole-2-carboxamido) -3-fluorophenyl) cyclohexane carboxylic acid; (1r, 4r) -4- (3-fluoro-4- (5- (2,4,5-trifluorophenylamino) -1,3,4-oxadiazole-2-carboxamido) phenyl) cyclohexanecarboxylic acid; (1s , 4s) -4- (4- (5- (3,4-difluorophenylamino) -1,3,4-oxadiazole-2-carboxamido) -3-fluorophenyl) cyclohexanecarboxylic acid and (1s, 4s) -4- (3 -fluoro-4- (5- (2,4,5-trifluorophenylamino) -1,3,4-oxadiazole-2-carboxamido) phenyl) |
| priorityDate | 2008-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 130.